FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease1
- 15 April 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (7) , 933-940
- https://doi.org/10.1097/01.tp.0000057831.93385.7d
Abstract
Background. Graft-versus-host (GVH) reactions contribute to stable engraftment of allogeneic hematopoietic stem cell transplants. It was hypothesized that the in vivo expansion of recipient dendritic cells (DC) with the administration of ligand for Flt3 (FL) could promote allogeneic engraftment after reduced-intensity conditioning by enhancing the GVH effect. Methods. FL was first administered to three nonirradiated healthy dogs for 13 days at a dosage of 100 μg/kg/day. Next, nine dogs received 4.5 Gy total-body irradiation (TBI) and unmodified marrow grafts from dog leukocyte antigen (DLA)-identical littermates without posttransplant immunosuppression. FL was administered to the recipients at a dosage of 100 μg/kg/day from day −7 until day +5. Results. In normal dogs, FL produced significant increases in monocytes (CD14+) and neutrophils in the peripheral blood, a marked increase in CD1c+ cells with DC-type morphology in lymph nodes, and increased alloreactivity of third-party responders to peripheral blood mononuclear cells in mixed lymphocyte reactions (P P =0.02, logistic regression). All engrafted FL-treated dogs became stable complete (n=2) or mixed (n=6) hematopoietic chimeras without significant graft-versus-host disease (GVHD). Recipient chimeric dogs (n=4) were tolerant to skin transplants from their marrow donors but rejected skin grafts from unrelated dogs within 7 to 9 days (median, 8 days). Conclusions. In this study, the authors showed that FL administered to recipients promotes stable engraftment of allogeneic marrow from DLA-identical littermates after 4.5 Gy TBI without significant GVHD.Keywords
This publication has 29 references indexed in Scilit:
- Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras1Transplantation, 2002
- Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host diseaseBlood, 2002
- Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsBlood, 2001
- Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethalityTransplantation and Cellular Therapy, 2001
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- THE USE OF AN ANTI-TCR???? MONOCLONAL ANTIBODY TO CONTROL HOST-VERSUS-GRAFT REACTIONS IN CANINE MARROW ALLOGRAFT RECIPIENTS CONDITIONED WITH LOW DOSE TOTAL BODY IRRADIATION1Transplantation, 1999
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.The Journal of Experimental Medicine, 1996
- HISTOCOMPATIBILITY TESTING OF DOG FAMILIES WITH HIGHLY POLYMORPHIC MICROSATELLITE MARKERS1Transplantation, 1996
- DLA-IDENTICAL MARROW GRAFTS AFTER LOW-DOSE TOTAL-BODY IRRADIATIONTransplantation, 1995
- USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTINGTransplantation, 1994